btaf45

Many social media posts by Tesla CEO on his platform are indiscernible from those of white supremacists, say experts

A potentially groundbreaking vaccine for seasonal flu would not be getting approval from regulators. In fact, it wasn’t even getting formal consideration, Moderna announced in a Tuesday press release, because officials were refusing to accept the application.

This is not the type of development you would normally expect a pharmaceutical company to broadcast. But that’s because there’s nothing normal about the way the federal government is behaving in this saga—or, for that matter, how the government has been behaving ever since President Donald Trump put anti-vaccination crusader Robert F. Kennedy Jr. in charge of America’s public health.

This was not a decision to reject the Moderna vaccine. It was a refusal even to think about approving it. The FDA rarely takes such a step, and when it does it’s usually because an application is missing a whole component or includes suspect data. Nobody is suggesting Moderna’s application has those kinds of issues.

On the contrary, the available evidence suggests this is a case of the FDA disqualifying a vaccine on questionable grounds, while changing its standards for review late in the process because it was trying to find a way to reject the vaccine. And based on reporting in outlets like STAT and the Wall Street Journal—along with some details I was able to confirm myself—the decision didn’t come from senior career staff working most closely on the application.1 They actually thought the review should go forward. The decision to refuse instead came directly from Vinay Prasad, a physician-researcher whom Kennedy installed as director of the FDA’s vaccines and biologics division.2

A director overruling career staff on a decision of this magnitude is highly unusual. But it’s indicative of the Trump administration’s broader, dramatic departure from past practices that had emphasized careful deliberation, input from staff and outside experts and lots of public discussion.

NASA's largest library at the Goddard Space Flight Center in Greenbelt, Maryland, which has been a central research hub for the global space agency since 1959, will be permanently closing on Friday (Jan 2). The closure of the 100,000-volume library is part of the Donald Trump administration's reorganisation drive, under which 13 buildings and over 100 science and engineering laboratories will be shut down on the 1.270-acre campus by March 2026

According to a statement posted on the website of the Goddard Engineers, Scientists and Technicians Association, specialised equipment and electronics designed to test spacecraft have already been removed and thrown out.

Senator Chris Van Hollen, Democrat of Maryland, said he will continue to raise his voice against the Trump administration's haphazard closure of the library.

“The Trump Administration has spent the last year attacking NASA Goddard and its work force and threatening our efforts to explore space, deepen our understanding of Earth, and spur technological advancements that make our economy stronger and nation safer,” said Van Hollen.

“These reports of closures at Goddard are deeply concerning. I will continue to push back on any actions that impact Goddard's critical mission," he added.

Next-generation vaccines could make the flu season less of a snot-filled nightmare—if they ever reach the public, that is. Trial data out this week shows that Pfizer’s mRNA-based flu vaccine performed markedly better than a traditional shot.

On Wednesday, researchers published the results of a Phase III trial on the vaccine, funded by Pfizer, in the New England Journal of Medicine. The experimental vaccine was significantly more effective at preventing flu than a standard vaccine, the researchers found. The vaccine appears to cause slightly more side effects than others, but there’s a bigger concern: It’s uncertain whether it will be approved in the U.S., given the government’s current skepticism and fearmongering around mRNA vaccine technology.

There were noticeably fewer confirmed cases of influenza in the modRNA group compared to the control vaccine group (57 vs 87), the study showed. Overall, the modRNA vaccine was 34.5% more effective at preventing flu-like illness.

“Donald Trump and Greg Abbott played with fire, got burned -- and democracy won,” California Gov. Gavin Newsom, a Democrat, posted on X after the Texas ruling, mentioning his Republican counterpart in Texas along with the president.

After a federal court panel struck down Republicans’ new map in Texas on Tuesday, the entire exercise holds the potential to net Democrats more winnable seats in the House instead.

“Trump may have let the genie out of the bottle,” said UCLA law professor Rick Hasen, “but he may not get the wish he’d hoped for.”

And when one party moves aggressively to draw lines to help itself win elections — also known as gerrymandering — it runs the risk of pushing its rival party to do the same.

That’s what Trump ended up doing, spurring California voters to replace their map drawn by a nonpartisan commission with one drawn by Democrats to gain five seats. If successful, the move would cancel out the action taken by Texas Republicans. California voters approved that map earlier this month, and if a Republican lawsuit fails to block it, that map giving Democrats more winnable seats will remain in effect even if Texas’ remains stalled.